APO Research
Talk to an analyst

APO RESEARCH · REPORT

Antitumor ADC Drugs

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Antitumor ADC Drugs Industry Growth and Trends Forecast to 2032

28 December 202597 pages

Choose your research edition.

Industry ResearchAntitumor ADC Drugs Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Antitumor ADC Drugs Industry Growth and Trends Forecast to 203297 pages · $3,450 USDMarket StructureGlobal Antitumor ADC Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032183 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Antitumor ADC Drugs Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Antitumor ADC Drugs Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Antitumor ADC Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Antitumor ADC Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Antitumor ADC Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Antitumor ADC Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Antitumor ADC Drugs include ADC Therapeutics, Daiichi Sankyo, Genmab, Immunomedics, Rakuten Medical, Seattle Medical Associates, GSK, Roche and RemeGen, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Antitumor ADC Drugs market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Antitumor ADC Drugs market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Antitumor ADC Drugs market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Antitumor ADC Drugs.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Antitumor ADC Drugs market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Antitumor ADC Drugs Market by Company

ADC Therapeutics

Daiichi Sankyo

Genmab

Immunomedics

Rakuten Medical

Seattle Medical Associates

GSK

Roche

RemeGen

Antitumor ADC Drugs Segment by Type

DNA Damaging Drugs

Tubulin Inhibitors

Antitumor ADC Drugs Segment by Application

Breast Cancer

Lymphoma

Other

Antitumor ADC Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Antitumor ADC Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Antitumor ADC Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Antitumor ADC Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Antitumor ADC Drugs manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Antitumor ADC Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of DNA Damaging Drugs Table 2. Major Company of Tubulin Inhibitors Table 3. Global Antitumor ADC Drugs Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Global Antitumor ADC Drugs Sales by Type (2021-2026) & (K Units) Table 5. Global Antitumor ADC Drugs Sales Market Share in Volume by Type (2021-2026) Table 6. Global Antitumor ADC Drugs Sales by Type (2021-2026) & (US$ Million) Table 7. Global Antitumor ADC Drugs Sales Market Share in Value by Type (2021-2026) Table 8. Global Antitumor ADC Drugs Price by Type (2021-2026) & (US$/Unit) Table 9. Global Antitumor ADC Drugs Sales by Type (2027-2032) & (K Units) Table 10. Global Antitumor ADC Drugs Sales Market Share in Volume by Type (2027-2032) Table 11. Global Antitumor ADC Drugs Sales by Type (2027-2032) & (US$ Million) Table 12. Global Antitumor ADC Drugs Sales Market Share in Value by Type (2027-2032) Table 13. Global Antitumor ADC Drugs Price by Type (2027-2032) & (US$/Unit) Table 14. North America Antitumor ADC Drugs Sales by Type (2021-2026) & (K Units) Table 15. North America Antitumor ADC Drugs Sales by Type (2021-2026) & (US$ Million) Table 16. Europe Antitumor ADC Drugs Sales by Type (2021-2026) & (K Units) Table 17. Europe Antitumor ADC Drugs Sales by Type (2021-2026) & (US$ Million) Table 18. Asia-Pacific Antitumor ADC Drugs Sales by Type (2021-2026) & (K Units) Table 19. Asia-Pacific Antitumor ADC Drugs Sales by Type (2021-2026) & (US$ Million) Table 20. Latin America Antitumor ADC Drugs Sales by Type (2021-2026) & (K Units) Table 21. Latin America Antitumor ADC Drugs Sales by Type (2021-2026) & (US$ Million) Table 22. Middle East and Africa Antitumor ADC Drugs Sales by Type (2021-2026) & (K Units) Table 23. Middle East and Africa Antitumor ADC Drugs Sales by Type (2021-2026) & (US$ Million) Table 24. Antitumor ADC Drugs Industry Trends Table 25. Antitumor ADC Drugs Industry Drivers Table 26. Antitumor ADC Drugs Industry Opportunities and Challenges Table 27. Antitumor ADC Drugs Industry Restraints Table 28. Global Antitumor ADC Drugs Sales Revenue by Company (US$ Million) & (2021-2026) Table 29. Global Antitumor ADC Drugs Revenue Market Share by Company (2021-2026) Table 30. Global Antitumor ADC Drugs Sales by Company (2021-2026) & (K Units) Table 31. Global Antitumor ADC Drugs Sales Share by Company (2021-2026) Table 32. Global Antitumor ADC Drugs Market Price by Company (2021-2026) & (US$/Unit) Table 33. Global Antitumor ADC Drugs Industry Company Ranking, 2024 VS 2025 VS 2026 Table 34. Global Antitumor ADC Drugs Major Company Production Sites and Headquarters Table 35. Global Antitumor ADC Drugs Company, Product Type & Application Table 36. Global Antitumor ADC Drugs Company Establishment Date Table 37. Global Company Market Concentration Ratio (CR5 and HHI) Table 38. Global Antitumor ADC Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 39. Global Antitumor ADC Drugs Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 40. Global Antitumor ADC Drugs Sales by Region (2021-2026) & (K Units) Table 41. Global Antitumor ADC Drugs Sales Market Share in Volume by Region (2021-2026) Table 42. Global Antitumor ADC Drugs Sales by Region (2021-2026) & (US$ Million) Table 43. Global Antitumor ADC Drugs Sales Market Share in Value by Region (2021-2026) Table 44. Global Antitumor ADC Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 45. Global Antitumor ADC Drugs Sales by Region (2027-2032) & (K Units) Table 46. Global Antitumor ADC Drugs Sales Market Share in Volume by Region (2027-2032) Table 47. Global Antitumor ADC Drugs Sales by Region (2027-2032) & (US$ Million) Table 48. Global Antitumor ADC Drugs Sales Market Share in Value by Region (2027-2032) Table 49. Global Antitumor ADC Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 50. Global Antitumor ADC Drugs Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 51. Global Antitumor ADC Drugs Sales by Application (2021-2026) & (K Units) Table 52. Global Antitumor ADC Drugs Sales Market Share in Volume by Application (2021-2026) Table 53. Global Antitumor ADC Drugs Sales by Application (2021-2026) & (US$ Million) Table 54. Global Antitumor ADC Drugs Sales Market Share in Value by Application (2021-2026) Table 55. Global Antitumor ADC Drugs Price by Application (2021-2026) & (US$/Unit) Table 56. Global Antitumor ADC Drugs Sales by Application (2027-2032) & (K Units) Table 57. Global Antitumor ADC Drugs Sales Market Share in Volume by Application (2027-2032) Table 58. Global Antitumor ADC Drugs Sales by Application (2027-2032) & (US$ Million) Table 59. Global Antitumor ADC Drugs Sales Market Share in Value by Application (2027-2032) Table 60. Global Antitumor ADC Drugs Price by Application (2027-2032) & (US$/Unit) Table 61. North America Antitumor ADC Drugs Sales by Application (2021-2026) & (K Units) Table 62. North America Antitumor ADC Drugs Sales by Application (2021-2026) & (US$ Million) Table 63. Europe Antitumor ADC Drugs Sales by Application (2021-2026) & (K Units) Table 64. Europe Antitumor ADC Drugs Sales by Application (2021-2026) & (US$ Million) Table 65. Asia-Pacific Antitumor ADC Drugs Sales by Application (2021-2026) & (K Units) Table 66. Asia-Pacific Antitumor ADC Drugs Sales by Application (2021-2026) & (US$ Million) Table 67. Latin America Antitumor ADC Drugs Sales by Application (2021-2026) & (K Units) Table 68. Latin America Antitumor ADC Drugs Sales by Application (2021-2026) & (US$ Million) Table 69. Middle East and Africa Antitumor ADC Drugs Sales by Application (2021-2026) & (K Units) Table 70. Middle East and Africa Antitumor ADC Drugs Sales by Application (2021-2026) & (US$ Million) Table 71. ADC Therapeutics Company Information Table 72. ADC Therapeutics Business Overview Table 73. ADC Therapeutics Antitumor ADC Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. ADC Therapeutics Antitumor ADC Drugs Product Portfolio Table 75. ADC Therapeutics Recent Development Table 76. Daiichi Sankyo Company Information Table 77. Daiichi Sankyo Business Overview Table 78. Daiichi Sankyo Antitumor ADC Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. Daiichi Sankyo Antitumor ADC Drugs Product Portfolio Table 80. Daiichi Sankyo Recent Development Table 81. Genmab Company Information Table 82. Genmab Business Overview Table 83. Genmab Antitumor ADC Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. Genmab Antitumor ADC Drugs Product Portfolio Table 85. Genmab Recent Development Table 86. Immunomedics Company Information Table 87. Immunomedics Business Overview Table 88. Immunomedics Antitumor ADC Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. Immunomedics Antitumor ADC Drugs Product Portfolio Table 90. Immunomedics Recent Development Table 91. Rakuten Medical Company Information Table 92. Rakuten Medical Business Overview Table 93. Rakuten Medical Antitumor ADC Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Rakuten Medical Antitumor ADC Drugs Product Portfolio Table 95. Rakuten Medical Recent Development Table 96. Seattle Medical Associates Company Information Table 97. Seattle Medical Associates Business Overview Table 98. Seattle Medical Associates Antitumor ADC Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Seattle Medical Associates Antitumor ADC Drugs Product Portfolio Table 100. Seattle Medical Associates Recent Development Table 101. GSK Company Information Table 102. GSK Business Overview Table 103. GSK Antitumor ADC Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. GSK Antitumor ADC Drugs Product Portfolio Table 105. GSK Recent Development Table 106. Roche Company Information Table 107. Roche Business Overview Table 108. Roche Antitumor ADC Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. Roche Antitumor ADC Drugs Product Portfolio Table 110. Roche Recent Development Table 111. RemeGen Company Information Table 112. RemeGen Business Overview Table 113. RemeGen Antitumor ADC Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 114. RemeGen Antitumor ADC Drugs Product Portfolio Table 115. RemeGen Recent Development Table 116. North America Antitumor ADC Drugs Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 117. North America Antitumor ADC Drugs Sales by Country (2021-2026) & (K Units) Table 118. North America Antitumor ADC Drugs Sales Market Share by Country (2021-2026) Table 119. North America Antitumor ADC Drugs Sales Forecast by Country (2027-2032) & (K Units) Table 120. North America Antitumor ADC Drugs Sales Market Share Forecast by Country (2027-2032) Table 121. North America Antitumor ADC Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 122. North America Antitumor ADC Drugs Market Size by Country (2021-2026) & (US$ Million) Table 123. North America Antitumor ADC Drugs Market Share by Country (2021-2026) Table 124. North America Antitumor ADC Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 125. North America Antitumor ADC Drugs Market Share Forecast by Country (2027-2032) Table 126. Europe Antitumor ADC Drugs Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 127. Europe Antitumor ADC Drugs Sales by Country (2021-2026) & (K Units) Table 128. Europe Antitumor ADC Drugs Sales Market Share by Country (2021-2026) Table 129. Europe Antitumor ADC Drugs Sales Forecast by Country (2027-2032) & (K Units) Table 130. Europe Antitumor ADC Drugs Sales Market Share Forecast by Country (2027-2032) Table 131. Europe Antitumor ADC Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 132. Europe Antitumor ADC Drugs Market Size by Country (2021-2026) & (US$ Million) Table 133. Europe Antitumor ADC Drugs Market Share by Country (2021-2026) Table 134. Europe Antitumor ADC Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 135. Europe Antitumor ADC Drugs Market Share Forecast by Country (2027-2032) Table 136. Asia-Pacific Antitumor ADC Drugs Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 137. Asia-Pacific Antitumor ADC Drugs Sales by Country (2021-2026) & (K Units) Table 138. Asia-Pacific Antitumor ADC Drugs Sales Market Share by Country (2021-2026) Table 139. Asia-Pacific Antitumor ADC Drugs Sales Forecast by Country (2027-2032) & (K Units) Table 140. Asia-Pacific Antitumor ADC Drugs Sales Market Share Forecast by Country (2027-2032) Table 141. Asia-Pacific Antitumor ADC Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 142. Asia-Pacific Antitumor ADC Drugs Market Size by Country (2021-2026) & (US$ Million) Table 143. Asia-Pacific Antitumor ADC Drugs Market Share by Country (2021-2026) Table 144. Asia-Pacific Antitumor ADC Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 145. Asia-Pacific Antitumor ADC Drugs Market Share Forecast by Country (2027-2032) Table 146. Latin America Antitumor ADC Drugs Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 147. Latin America Antitumor ADC Drugs Sales by Country (2021-2026) & (K Units) Table 148. Latin America Antitumor ADC Drugs Sales Market Share by Country (2021-2026) Table 149. Latin America Antitumor ADC Drugs Sales Forecast by Country (2027-2032) & (K Units) Table 150. Latin America Antitumor ADC Drugs Sales Market Share Forecast by Country (2027-2032) Table 151. Latin America Antitumor ADC Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 152. Latin America Antitumor ADC Drugs Market Size by Country (2021-2026) & (US$ Million) Table 153. Latin America Antitumor ADC Drugs Market Share by Country (2021-2026) Table 154. Latin America Antitumor ADC Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 155. Latin America Antitumor ADC Drugs Market Share Forecast by Country (2027-2032) Table 156. Middle East and Africa Antitumor ADC Drugs Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 157. Middle East and Africa Antitumor ADC Drugs Sales by Country (2021-2026) & (K Units) Table 158. Middle East and Africa Antitumor ADC Drugs Sales Market Share by Country (2021-2026) Table 159. Middle East and Africa Antitumor ADC Drugs Sales Forecast by Country (2027-2032) & (K Units) Table 160. Middle East and Africa Antitumor ADC Drugs Sales Market Share Forecast by Country (2027-2032) Table 161. Middle East and Africa Antitumor ADC Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 162. Middle East and Africa Antitumor ADC Drugs Market Size by Country (2021-2026) & (US$ Million) Table 163. Middle East and Africa Antitumor ADC Drugs Market Share by Country (2021-2026) Table 164. Middle East and Africa Antitumor ADC Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 165. Middle East and Africa Antitumor ADC Drugs Market Share Forecast by Country (2027-2032) Table 166. Key Raw Materials Table 167. Raw Materials Key Suppliers Table 168. Antitumor ADC Drugs Distributors List Table 169. Antitumor ADC Drugs Customers List Table 170. Research Programs/Design for This Report Table 171. Authors List of This Report Table 172. Secondary Sources Table 173. Primary Sources List of Figures Figure 1. Antitumor ADC Drugs Image Figure 2. Global Antitumor ADC Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Antitumor ADC Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Antitumor ADC Drugs Sales (2021-2032) & (K Units) Figure 5. DNA Damaging Drugs Image Figure 6. Global DNA Damaging Drugs Sales YoY Growth (2021-2032) & (K Units) Figure 7. Tubulin Inhibitors Image Figure 8. Global Tubulin Inhibitors Sales YoY Growth (2021-2032) & (K Units) Figure 9. Global Antitumor ADC Drugs Market Size Overview by Type (2021-2032) & (US$ Million) Figure 10. Global Antitumor ADC Drugs Market Share by Type 2025 VS 2032 Figure 11. North America Antitumor ADC Drugs Sales Market Share in Volume by Type in 2025 Figure 12. North America Antitumor ADC Drugs Sales Market Share in Value by Type in 2025 Figure 13. Europe Antitumor ADC Drugs Sales Market Share in Volume by Type in 2025 Figure 14. Europe Antitumor ADC Drugs Sales Market Share in Value by Type in 2025 Figure 15. Asia-Pacific Antitumor ADC Drugs Sales Market Share in Volume by Type in 2025 Figure 16. Asia-Pacific Antitumor ADC Drugs Sales Market Share in Value by Type in 2025 Figure 17. Latin America Antitumor ADC Drugs Sales Market Share in Volume by Type in 2025 Figure 18. Latin America Antitumor ADC Drugs Sales Market Share in Value by Type in 2025 Figure 19. Middle East and Africa Antitumor ADC Drugs Sales Market Share in Volume by Type in 2025 Figure 20. Middle East and Africa Antitumor ADC Drugs Sales Market Share in Value by Type in 2025 Figure 21. Global Top 5 and 10 Antitumor ADC Drugs Players Market Share by Revenue in 2025 Figure 22. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 23. Breast Cancer Image Figure 24. Global Breast Cancer Sales YoY Growth (2021-2032) & (K Units) Figure 25. Lymphoma Image Figure 26. Global Lymphoma Sales YoY Growth (2021-2032) & (K Units) Figure 27. Other Image Figure 28. Global Other Sales YoY Growth (2021-2032) & (K Units) Figure 29. Global Antitumor ADC Drugs Market Size Overview by Application (2021-2032) & (US$ Million) Figure 30. Global Antitumor ADC Drugs Market Share by Application 2025 VS 2032 Figure 31. North America Antitumor ADC Drugs Sales Market Share in Volume by Application in 2025 Figure 32. North America Antitumor ADC Drugs Sales Market Share in Value by Application in 2025 Figure 33. Europe Antitumor ADC Drugs Sales Market Share in Volume by Application in 2025 Figure 34. Europe Antitumor ADC Drugs Sales Market Share in Value by Application in 2025 Figure 35. Asia-Pacific Antitumor ADC Drugs Sales Market Share in Volume by Application in 2025 Figure 36. Asia-Pacific Antitumor ADC Drugs Sales Market Share in Value by Application in 2025 Figure 37. Latin America Antitumor ADC Drugs Sales Market Share in Volume by Application in 2025 Figure 38. Latin America Antitumor ADC Drugs Sales Market Share in Value by Application in 2025 Figure 39. Middle East and Africa Antitumor ADC Drugs Sales Market Share in Volume by Application in 2025 Figure 40. Middle East and Africa Antitumor ADC Drugs Sales Market Share in Value by Application in 2025 Figure 41. North America Antitumor ADC Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 42. North America Antitumor ADC Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 43. North America Antitumor ADC Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 44. North America Antitumor ADC Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 45. Europe Antitumor ADC Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 46. Europe Antitumor ADC Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 47. Europe Antitumor ADC Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. Europe Antitumor ADC Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Asia-Pacific Antitumor ADC Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 50. Asia-Pacific Antitumor ADC Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. Asia-Pacific Antitumor ADC Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. Asia-Pacific Antitumor ADC Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Latin America Antitumor ADC Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 54. Latin America Antitumor ADC Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Latin America Antitumor ADC Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Latin America Antitumor ADC Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Middle East and Africa Antitumor ADC Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 58. Middle East and Africa Antitumor ADC Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Middle East and Africa Antitumor ADC Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Middle East and Africa Antitumor ADC Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Antitumor ADC Drugs Value Chain Figure 62. Key Raw Materials Price Figure 63. Manufacturing Cost Structure Figure 64. Antitumor ADC Drugs Production Mode & Process Figure 65. Direct Comparison with Distribution Share Figure 66. Distributors Profiles Figure 67. Years Considered Figure 68. Research Process Figure 69. Key Executives Interviewed

Scope & coverage.

Types
  • DNA Damaging Drugs
  • Tubulin Inhibitors
Applications
  • Breast Cancer
  • Lymphoma
  • Other
Companies covered
  • ADC Therapeutics
  • Daiichi Sankyo
  • Genmab
  • Immunomedics
  • Rakuten Medical
  • Seattle Medical Associates
  • GSK
  • Roche
  • RemeGen

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Antitumor ADC Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Antitumor ADC Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Antitumor ADC Drugs Market by Type
  6. 1.3.1 DNA Damaging Drugs
  7. 1.3.2 Tubulin Inhibitors
  8. 1.4 Global Antitumor ADC Drugs Market Size by Type
  9. 1.4.1 Global Antitumor ADC Drugs Market Size Overview by Type (2021-2032)
  10. 1.4.2 Global Antitumor ADC Drugs Historic Market Size Review by Type (2021-2026)
  11. 1.4.3 Global Antitumor ADC Drugs Forecasted Market Size by Type (2027-2032)
  12. 1.5 Key Regions Market Size by Type
  13. 1.5.1 North America Antitumor ADC Drugs Sales Breakdown by Type (2021-2026)
  14. 1.5.2 Europe Antitumor ADC Drugs Sales Breakdown by Type (2021-2026)
  15. 1.5.3 Asia-Pacific Antitumor ADC Drugs Sales Breakdown by Type (2021-2026)
  16. 1.5.4 South America Antitumor ADC Drugs Sales Breakdown by Type (2021-2026)
  17. 1.5.5 Middle East and Africa Antitumor ADC Drugs Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Antitumor ADC Drugs Industry Trends
  2. 2.2 Antitumor ADC Drugs Industry Drivers
  3. 2.3 Antitumor ADC Drugs Industry Opportunities and Challenges
  4. 2.4 Antitumor ADC Drugs Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Antitumor ADC Drugs Revenue (2021-2026)
  2. 3.2 Global Top Players by Antitumor ADC Drugs Sales (2021-2026)
  3. 3.3 Global Top Players by Antitumor ADC Drugs Price (2021-2026)
  4. 3.4 Global Antitumor ADC Drugs Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Antitumor ADC Drugs Major Company Production Sites & Headquarters
  6. 3.6 Global Antitumor ADC Drugs Company, Product Type & Application
  7. 3.7 Global Antitumor ADC Drugs Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Antitumor ADC Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Antitumor ADC Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Antitumor ADC Drugs Tier 1, Tier 2, and Tier 3
4 Antitumor ADC Drugs Regional Status and Outlook
  1. 4.1 Global Antitumor ADC Drugs Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Antitumor ADC Drugs Historic Market Size by Region
  3. 4.2.1 Global Antitumor ADC Drugs Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Antitumor ADC Drugs Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Antitumor ADC Drugs Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Antitumor ADC Drugs Forecasted Market Size by Region
  7. 4.3.1 Global Antitumor ADC Drugs Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Antitumor ADC Drugs Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Antitumor ADC Drugs Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Antitumor ADC Drugs by Application
  1. 5.1 Antitumor ADC Drugs Market by Application
  2. 5.1.1 Breast Cancer
  3. 5.1.2 Lymphoma
  4. 5.1.3 Other
  5. 5.2 Global Antitumor ADC Drugs Market Size by Application
  6. 5.2.1 Global Antitumor ADC Drugs Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Antitumor ADC Drugs Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Antitumor ADC Drugs Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Antitumor ADC Drugs Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Antitumor ADC Drugs Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Antitumor ADC Drugs Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Antitumor ADC Drugs Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Antitumor ADC Drugs Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 ADC Therapeutics
  2. 6.1.1 ADC Therapeutics Company Information
  3. 6.1.2 ADC Therapeutics Business Overview
  4. 6.1.3 ADC Therapeutics Antitumor ADC Drugs Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 ADC Therapeutics Antitumor ADC Drugs Product Portfolio
  6. 6.1.5 ADC Therapeutics Recent Developments
  7. 6.2 Daiichi Sankyo
  8. 6.2.1 Daiichi Sankyo Company Information
  9. 6.2.2 Daiichi Sankyo Business Overview
  10. 6.2.3 Daiichi Sankyo Antitumor ADC Drugs Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Daiichi Sankyo Antitumor ADC Drugs Product Portfolio
  12. 6.2.5 Daiichi Sankyo Recent Developments
  13. 6.3 Genmab
  14. 6.3.1 Genmab Company Information
  15. 6.3.2 Genmab Business Overview
  16. 6.3.3 Genmab Antitumor ADC Drugs Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Genmab Antitumor ADC Drugs Product Portfolio
  18. 6.3.5 Genmab Recent Developments
  19. 6.4 Immunomedics
  20. 6.4.1 Immunomedics Company Information
  21. 6.4.2 Immunomedics Business Overview
  22. 6.4.3 Immunomedics Antitumor ADC Drugs Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Immunomedics Antitumor ADC Drugs Product Portfolio
  24. 6.4.5 Immunomedics Recent Developments
  25. 6.5 Rakuten Medical
  26. 6.5.1 Rakuten Medical Company Information
  27. 6.5.2 Rakuten Medical Business Overview
  28. 6.5.3 Rakuten Medical Antitumor ADC Drugs Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Rakuten Medical Antitumor ADC Drugs Product Portfolio
  30. 6.5.5 Rakuten Medical Recent Developments
  31. 6.6 Seattle Medical Associates
  32. 6.6.1 Seattle Medical Associates Company Information
  33. 6.6.2 Seattle Medical Associates Business Overview
  34. 6.6.3 Seattle Medical Associates Antitumor ADC Drugs Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Seattle Medical Associates Antitumor ADC Drugs Product Portfolio
  36. 6.6.5 Seattle Medical Associates Recent Developments
  37. 6.7 GSK
  38. 6.7.1 GSK Company Information
  39. 6.7.2 GSK Business Overview
  40. 6.7.3 GSK Antitumor ADC Drugs Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 GSK Antitumor ADC Drugs Product Portfolio
  42. 6.7.5 GSK Recent Developments
  43. 6.8 Roche
  44. 6.8.1 Roche Company Information
  45. 6.8.2 Roche Business Overview
  46. 6.8.3 Roche Antitumor ADC Drugs Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Roche Antitumor ADC Drugs Product Portfolio
  48. 6.8.5 Roche Recent Developments
  49. 6.9 RemeGen
  50. 6.9.1 RemeGen Company Information
  51. 6.9.2 RemeGen Business Overview
  52. 6.9.3 RemeGen Antitumor ADC Drugs Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 RemeGen Antitumor ADC Drugs Product Portfolio
  54. 6.9.5 RemeGen Recent Developments
7 North America by Country
  1. 7.1 North America Antitumor ADC Drugs Sales by Country
  2. 7.1.1 North America Antitumor ADC Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Antitumor ADC Drugs Sales by Country (2021-2026)
  4. 7.1.3 North America Antitumor ADC Drugs Sales Forecast by Country (2027-2032)
  5. 7.2 North America Antitumor ADC Drugs Market Size by Country
  6. 7.2.1 North America Antitumor ADC Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Antitumor ADC Drugs Market Size by Country (2021-2026)
  8. 7.2.3 North America Antitumor ADC Drugs Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Antitumor ADC Drugs Sales by Country
  2. 8.1.1 Europe Antitumor ADC Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Antitumor ADC Drugs Sales by Country (2021-2026)
  4. 8.1.3 Europe Antitumor ADC Drugs Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Antitumor ADC Drugs Market Size by Country
  6. 8.2.1 Europe Antitumor ADC Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Antitumor ADC Drugs Market Size by Country (2021-2026)
  8. 8.2.3 Europe Antitumor ADC Drugs Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Antitumor ADC Drugs Sales by Country
  2. 9.1.1 Asia-Pacific Antitumor ADC Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Antitumor ADC Drugs Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Antitumor ADC Drugs Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Antitumor ADC Drugs Market Size by Country
  6. 9.2.1 Asia-Pacific Antitumor ADC Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Antitumor ADC Drugs Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Antitumor ADC Drugs Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Antitumor ADC Drugs Sales by Country
  2. 10.1.1 South America Antitumor ADC Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Antitumor ADC Drugs Sales by Country (2021-2026)
  4. 10.1.3 South America Antitumor ADC Drugs Sales Forecast by Country (2027-2032)
  5. 10.2 South America Antitumor ADC Drugs Market Size by Country
  6. 10.2.1 South America Antitumor ADC Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Antitumor ADC Drugs Market Size by Country (2021-2026)
  8. 10.2.3 South America Antitumor ADC Drugs Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Antitumor ADC Drugs Sales by Country
  2. 11.1.1 Middle East and Africa Antitumor ADC Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Antitumor ADC Drugs Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Antitumor ADC Drugs Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Antitumor ADC Drugs Market Size by Country
  6. 11.2.1 Middle East and Africa Antitumor ADC Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Antitumor ADC Drugs Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Antitumor ADC Drugs Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Antitumor ADC Drugs Value Chain Analysis
  2. 12.1.1 Antitumor ADC Drugs Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Antitumor ADC Drugs Production Mode & Process
  7. 12.2 Antitumor ADC Drugs Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Antitumor ADC Drugs Distributors
  10. 12.2.3 Antitumor ADC Drugs Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst